Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 42
- Registration Number
- NCT05095207
- Locations
- ๐บ๐ธ
Mount Sinai Beth Israel, New York, New York, United States
๐บ๐ธMount Sinai - West, New York, New York, United States
๐บ๐ธDubin breast Center, New York, New York, United States
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer๏ผMAPS๏ผ
- Conditions
- Salivary Gland Neoplasms
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Target Recruit Count
- 182
- Registration Number
- NCT05087706
- Locations
- ๐จ๐ณ
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- Conditions
- Prostate Adenocarcinoma
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
๐บ๐ธBanner MD Anderson Cancer Center, Gilbert, Arizona, United States
๐บ๐ธArizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
SRT Versus SRT+ADT in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Marco Lorenzo Bonu
- Target Recruit Count
- 310
- Registration Number
- NCT05019846
- Locations
- ๐ฎ๐น
ASST Spedali Civili of Brescia, Brescia, BS, Italy
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Radiation: Stereotactic body radiation therapy
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Alessa Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04943536
- Locations
- ๐บ๐ธ
National Cancer Institute, Bethesda, Maryland, United States
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- Conditions
- Recurrent Prostate CancerProstate CancerOligometastasisOligorecurrenceDe Novo Prostate CancerMetastatic Prostate Cancer
- Interventions
- Procedure: PET-directed Local Therapy using SurgeryRadiation: PET-directed Local Therapy using RadiationOther: Salvage Local Therapy for locally recurrent diseaseRadiation: Prostate-directed Radiation for De novo oligometastatic prostate cancer
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 464
- Registration Number
- NCT04787744
- Locations
- ๐บ๐ธ
VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States
๐บ๐ธVA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
๐บ๐ธBay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Conditions
- Stage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
- Interventions
- Other: Questionnaire Administration
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT04734730
- Locations
- ๐บ๐ธ
City of Hope Medical Center, Duarte, California, United States
Camostat With Bicalutamide for COVID-19
- Conditions
- SARS-CoV InfectionCovid19Coronavirus Infection
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2023-10-06
- Target Recruit Count
- 6
- Registration Number
- NCT04652765
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital, Baltimore, Maryland, United States
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ElastographyProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2753
- Registration Number
- NCT04513717
- Locations
- ๐บ๐ธ
HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, United States
๐บ๐ธCarle Cancer Center, Urbana, Illinois, United States
๐บ๐ธSands Cancer Center, Canandaigua, New York, United States
Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- University of Florida
- Registration Number
- NCT04509999
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.